Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 4/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | CPB1 | P15086 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28880336 | 1.00 | OPRL1 (0.49) | OPRL1MITFMAPTHTTPREP | |
| SCHEMBL2072837 | 0.88 | NPSR1 (0.54) | MITFMAPTHTTPREPNPSR1 | |
| SCHEMBL13259971 | 0.87 | MEN1 (0.49) | OPRL1PREPNPSR1MEN1KMT2A | |
| SCHEMBL3148090 | 0.87 | MEN1 (0.51) | OPRL1PREPNPSR1MEN1KMT2A | |
| SCHEMBL628051 | 0.87 | MEN1 (0.51) | OPRL1PREPNPSR1MEN1KMT2A | |
| SCHEMBL628052 | 0.87 | MEN1 (0.51) | OPRL1PREPNPSR1MEN1KMT2A | |
| SCHEMBL1864842 | 0.83 | POLB (0.52) | MITFMAPTHTTPREPNPSR1 | |
| SCHEMBL7802196 | 0.83 | POLB (0.52) | MITFMAPTHTTPREPNPSR1 | |
| SCHEMBL2300448 | 0.83 | POLB (0.52) | MITFMAPTHTTPREPNPSR1 | |
| SCHEMBL15307912 | 0.82 | HTR2C (0.56) | PREPNPSR1MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108727407-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-105198908-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-10208127-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2018-12-13 | — | — | US | disclosed |
| CN-108727407-A | Novel benzodiazepine * derivatives | 伊缪诺金公司 | 2018-11-02 | — | — | CN | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| CN-102365021-A | Novel benzodiazepine derivatives | IMMUNOGEN INC | 2012-02-29 | — | — | CN | disclosed |
| EP-2393362-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | Immunogen, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091150-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | OPRL1 171/4885MITF 2990/4885MAPT 3500/4885 |
| US-20180355055-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | OPRL1 171/4885MITF 2990/4885MAPT 3500/4885 |
| US-10208127-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | OPRL1 181/4885MITF 2978/4885MAPT 3237/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | OPRL1 171/4885MITF 2990/4885MAPT 3500/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | OPRL1 171/4885MITF 2990/4885MAPT 3500/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | OPRL1 181/4885MITF 2978/4885MAPT 3237/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | OPRL1 181/4885MITF 2978/4885MAPT 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.